Table 1 Baseline patients’ characteristics
Neostigmine group (n = 34) | Sugammadex group (n = 36) | |
|---|---|---|
Age (years) | 53 (48–62) | 60 (56–64) |
Gender (male) | 17 (50.0%) | 20 (55.6%) |
Height (cm) | 167 (164–179) | 170 (163–177) |
Weight (kg) | 70 (61–81) | 71 (64–79) |
BMI (kg.m−2) | 25.0 (22.5–27.6) | 25.0 (22.4–26.3) |
Active smokers | 8 (23.5%) | 7 (19.4%) |
Past smokers | 12 (35.3%) | 18 (50.0%) |
ASA classes I–II | 32 (94.1%) | 35 (97.2%) |
FEV1 (% of predicted value) | 97 (88–107) | 99 (89–109) |
FEV1/FVC (%) | 80 (79–86) | 79 (73–84) |
DLCO (% of predicted value) | 79 (74–82) | 74 (64–83) |
DLCO/VA (% of predicted value) | 90 (82–98) | 89 (77–95) |
PaO2 (mmHg) | 80 (82–98) | 89 (77–95) |